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Although the concept of a leukemic stem cell system has recently been well accepted, its 
nature and the underlying molecular mechanisms remain obscure. Constitutive activation of 
signal transducers and activators of transcription 3 (STAT3) and STAT5 is frequently detected 
in various hematopoietic tumors. To evaluate their role in normal and leukemic stem cells, 
we took advantage of constitutively active STAT mutants to activate STAT signaling selectively 
in hematopoietic stem cells (HSCs). Activation of STAT5 in CD34
 
–
 
c-Kit
 
 
 
Sca-1
 
 
 
 lineage 
marker
 
–
 
 (CD34
 
–
 
KSL) HSCs led to a drastic expansion of multipotential progenitors and 
promoted HSC self-renewal ex vivo. In sharp contrast, STAT3 was demonstrated to be 
dispensable for the HSC maintenance in vivo, and its activation facilitated lineage 
commitment of HSCs in vitro. In a mouse model of myeloproliferative disease (MPD), 
sustained STAT5 activation in CD34
 
–
 
KSL HSCs but not in CD34
 
 
 
KSL multipotential 
progenitors induced fatal MPD, indicating that the capacity of STAT5 to promote self-
renewal of hematopoietic stem cells is crucial to MPD development. Our findings collectively 
establish a specific role for STAT5 in self-renewal of normal as well as leukemic stem cells.
 
Cytokine signaling pathways are important
signal mediators promoting hematopoietic
cell survival, proliferation, and differentiation.
The JAK–STAT pathway is recognized as a
common downstream pathway from cytokine
receptors and plays critical roles in transmit-
ting a variety of biological functions by acti-
vating transcription of various target genes.
STAT proteins form homo- or heterodimers
upon tyrosine phosphorylation, which usually
is mediated by JAKs. Dimerized STAT pro-
teins immediately enter the nucleus and bind
to specific DNA sequences in promoter re-
gions of various genes, resulting in gene acti-
vation or repression (1). To date, seven genes
encoding mammalian STAT family members
(STAT 1–6) have been identified. Among
them is STAT5, which is encoded by two
genes, 
 
STAT5A
 
 and 
 
STAT5B
 
, with 95% se-
quence identity (2).
Attempts to expand HSCs ex vivo have
been made under various conditions. These at-
tempts include manipulation of transcriptional
regulators such as HoxB4 and Bmi-1 (3, 4).
We and others have reported that among vari-
ous cytokines, thrombopoietin (TPO) promotes
the self-renewal of long-term repopulating
(LTR) HSCs in vitro (5, 6). BM cells from
mice deficient for c-
 
mpl
 
, the gene encoding
TPO receptor, failed to compete effectively
with normal cells for long-term reconstitution
of the hematopoietic organs of irradiated recip-
ients, even when transplanted in 10-fold excess
(7). These findings suggest that TPO signaling
is a prominent and essential physiological com-
ponent of HSC regulation. TPO was first char-
acterized as a key regulator of megakaryocyte
and platelet formation. TPO binding dimerizes
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c-mpl, thereby activating intracellular signaling cascades, in-
cluding JAK–STAT, phosphatidylinositol 3-kinase/Akt, and
Ras/mitogen-activated protein kinase pathways.
 
STAT5A
 
 and 
 
STAT5B
 
 doubly disrupted mice have
been generated recently. They displayed a profound defect
in competitive repopulation of hematopoiesis (8, 9). The
commitment of embryonic stem cells to hematopoietic cells
is augmented by a STAT5-mediated signal (10). A recent
study showed that persistent activation of STAT5A in hu-
man cord blood CD34
 
 
 
 cells enhances their capacity to re-
populate nonobese diabetic/SCID mice in the short term
and promotes erythroid differentiation (11). All these find-
ings suggest that STAT5 is significantly active downstream
in TPO signaling in HSCs. However, the role of STAT5 in
LTR-HSCs remains uncharacterized.
Emerging evidence suggests that cancer stem cells sustain
neoplasms. The idea of cancer stem cells is well established in
acute myeloid leukemia and MPD (12, 13). Leukemic stem
cells share self-renewal machineries, such as Bmi-1, with
normal HSCs and constantly regenerate leukemic progeny
with a limited proliferative and differentiation capacity (14,
15). One of the most recently recognized oncogenic signal-
ing pathways involves the STAT proteins. Constitutive acti-
vation of STAT3 and STAT5 is frequently detected in a va-
riety of tumor types (16). However, their contribution to
cancer stem cell system is hitherto untested.
We characterized specific functions of STAT3 and
STAT5 in LTR-HSCs by using their constitutively active
forms of mutants and highly purified mouse HSCs. We
clearly demonstrated that the activation of STAT5, but not
STAT3, promotes HSC self-renewal and that STAT3 is dis-
pensable for the maintenance of HSC in vivo. We further
showed that sustained STAT5 activation in CD34
 
–
 
KSL
HSCs, but not in CD34
 
 
 
c-Kit
 
 
 
Sca-1
 
 
 
 lineage marker
 
– 
 
(KSL)
progenitors, establishes MPD in mice, providing a good
mouse model of leukemic hematopoiesis that helps under-
stand a specific role for STAT5 in cancer stem cell systems.
 
RESULTS
STAT5 activation in HSCs
 
TPO promotes the self-renewal of LTR-HSCs in vitro (5, 6).
Whether TPO induces STAT5 activation in purified HSCs
has never been determined. CD34
 
 
 
KSL cells represent only
0.004% of BM mononuclear cells and are highly enriched for
LTR-HSCs (17). To visualize STAT5 activation in HSCs di-
rectly, we immunostained TPO-stimulated CD34
 
–
 
KSL cells
with an anti-phosho-STAT5A/B antibody (Fig. 1).
TPO stimulation induced high-level activation of
STAT5A/B. Upon TPO stimulation, STAT5A/B became
phosphorylated on tyrosine residues (Y694/Y699) and was
localized to the euchromatic region of the nucleus that is de-
void of DAPI staining. In contrast, IL-6 reportedly activates
STAT3 and failed to support in vitro HSC self-renewal in
our previous study (6). In fact, IL-6 stimulation of mouse
M1 immature myeloid cells did not induce STAT5 activa-
tion at all (unpublished data). Unexpectedly, however, IL-6
induced STAT5 activation in CD34
 
–
 
KSL cells. Neverthe-
less, the level of STAT5 activation was much weaker than
that induced by TPO, and the vast majority of phosphory-
lated STAT5 stayed in the cytoplasm. Although the reason a
substantial amount of phosphorylated STAT5 stays in the
cytoplasm remains obscure, these data indicate a major role
of STAT5 in TPO signaling in HSCs.
 
Characterization of constitutively active STAT3 
and STAT5 mutants
 
To examine STAT5-specific functions in HSCs, we used ret-
roviral constructs that express constitutively active STAT5A
mutants. These constructs previously have been shown to me-
diate functions of STAT5A/B (Fig. 2 A and references 18, 19).
As a control, a retroviral construct that expresses constitu-
tively active STAT3 mutant was also prepared (20). All mu-
tants except for STAT3C could confer cytokine indepen-
dence on a Ba/F3 IL-3–dependent pro-B cell line in a similar
fashion (18, 19, and unpublished data). Among STAT5 mu-
tants, however, STAT5 1
 
*
 
6 and STAT5 1
 
*
 
7 mutants could
mediate high-level transcriptional activation of a STAT5 tar-
get gene, whereas STAT5 #2 was less effective (Fig. 2 B).
Western blotting assessment showed comparable expression
of each mutant in transduced cells (Fig. 2 B).
 
Selective activation of STAT5 supports multilineage 
differentiation of HSCs
 
CD34
 
–
 
KSL cells are highly enriched for LTR-HSCs, of which
 
 
 
60% can be defined as colony-forming units-neutrophil/
Figure 1. Immunodetection of STAT activation in CD34 KSL cells. 
(A) CD34 KSL cells were sorted in a culture medium drop supplemented 
with TPO or IL-6 on fibronectin-coated slide glasses. After 30 min of incu-
bation at 37 C, STAT5 activation was assessed by immunocytological 
analysis using an anti-phospho-STAT5A/B. The localization of tyrosine-
phosphorylated STAT5 was determined under a confocal microscope. 
Nuclear DAPI staining (blue; left) and immunofluorescent labeling of 
STAT5 (green; middle) are merged (right). Bar, 4  m. 
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macrophage/Erythroblast/Megakaryocyte (CFU-nmEM), that
exhibit multilineage differentiation capacity in vitro (4). To
understand the role of STAT5 in proliferation and multilineage
differentiation of HSCs, we first transduced CD34
 
–
 
KSL cells
with indicated 
 
STAT5
 
 mutant retroviruses. At 24 h after trans-
duction, cells were subjected to the colony assay in the pres-
ence of stem cell factor (SCF) alone, a condition that does not
support proliferation or multilineage differentiation of HSCs.
In contrast to 
 
GFP
 
 control, CD34
 
–
 
KSL cells expressing
 
STAT5 1
 
*
 
6
 
 and 
 
STAT5 1
 
*
 
7
 
 retrovirus, but not 
 
STAT5 #2
 
 or
wild-type 
 
STAT5
 
 retroviruses, gave rise to a significant num-
ber of high-proliferative-potential colonies (colony diameter
 
 
 
1 mm). Morphological analysis demonstrated that colonies
generated from 
 
STAT5 1
 
*
 
6
 
– or 
 
STAT5 1
 
*
 
7
 
–expressing cells
include nmEM colonies that consist of multilineage cells (Fig.
2 C). On the other hand, CD34
 
–
 
KSL cells transduced with
 
STAT3C
 
 generated only a few colonies of neutrophils and
macrophages (Fig. 2 C). These data indicate that STAT5, but
not STAT3, mainly mediates growth and differentiation signals
in HSCs and their progeny.
 
Selective activation of STAT5 expands CFU-nmEM ex vivo
 
We next asked if STAT5 supports HSC self-renewal ex
vivo. CD34
 
–
 
KSL cells were transduced with each 
 
STAT
 
mutant and were further incubated for 13 d (14-d ex vivo
culture in total). In the presence of SCF and TPO, a condi-
tion that supports expansion of HSCs and progenitors rather
than their differentiation, forced expression of wild-type and
 
STAT5
 
 mutant gave no apparent growth advantage for the
first 10 d compared with the 
 
GFP
 
 control (Fig. 3 A).
Notably, however, at day 7 of culture, 
 
STAT5-
 
trans-
duced cells contained numerous HPP-CFCs (Fig. 3 B).
Morphological evaluation of the colonies revealed significant
expansion of CFU-nmEM by both wild-type and STAT5
mutants. Given that 60% of freshly isolated CD34
 
–
 
KSL cells
can be defined as CFU-nmEM (4), a net expansion in CFU-
nmEM by 10- (wild-type STAT5) to 20-fold (STAT5 1
 
*
 
6)
occurred during 7-d culture (Fig. 3 C). Even when supple-
mented with SCF alone, cells expressing 
 
STAT5 1
 
*
 
6
 
 or
 
STAT5 1
 
*
 
7
 
 showed mitotic activity that was significant, al-
beit weaker than that seen in the presence of SCF and TPO
Figure 2. Selective activation of STAT5 supports multilineage 
differentiation of HSCs. (A) Schematic representation of the retroviral 
vector GCDNsam-IRES-EGFP harboring constitutively active STAT3 and 
STAT5A mutant genes. Positions of point mutations are indicated.   , 
packaging signal; SD, splice donor; SA, splice acceptor; DBD, DNA binding 
domain; SH2, src homology domain 2; ED, effector domain. (B) Transcrip-
tional activity and expression of STAT5A mutants. NIH 3T3 cells were 
cotransfected with 3x D1-SIE1-Luc luciferase reporter gene and pGCDN-
sam-IRES-EGFP (GFP), pGCDNsam-wild-type STAT5A-IRES-EGFP (WT), 
pGCDNsam-STAT5A #2-IRES-EGFP (#2), pGCDNsam-STAT5A 1*6-IRES-
EGFP (1*6), or pGCDNsam-STAT5A 1*7-IRES-EGFP (1*7). The results are 
shown as the mean   SD of triplicate cultures (top). Jurkat cells trans-
duced with the indicated retroviruses were selected by cell sorting using 
GFP as a marker and then subjected to Western blot analysis using anti-
mouse STAT5A and anti- -tubulin antibodies (bottom). (C) Selective acti-
vation of STATs in HSCs. CD34 KSL cells transduced with the indicated 
STAT5 mutants were subjected to colony assays in the presence of SCF 
only. The numbers of HPP-CFCs were retrospectively evaluated by counting 
colonies at d 10. Colonies derived from HPP-CFCs were recovered and 
examined for their composition with respect to CFCs. The results are 
shown as mean   SD of triplicate cultures. *, statistically significant 
against GFP control ( 0.01). 
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Figure 3. Ex vivo expansion of CFU-nmEM by selective activation 
of STAT5 in HSCs. (A) Growth of CD34–KSL cells transduced with STAT5 
mutants. CD34–KSL cells transduced with the indicated retroviruses were 
cultured in the presence of SCF alone or of both SCF and TPO. The results 
are shown as mean   SD of triplicate cultures. (B) Colony assays. At d 7 
of culture, colony assays were performed to evaluate the content of 
HPP-CFC in culture. The colonies derived from HPP-CFCs were recovered 
and examined by microscopy to determine colony types. The results are 
shown as mean   SD of triplicate cultures. *, statistically significant 
against GFP control ( 0.02). (C) Net expansion of CFU-nmEM during the 
7-d culture period. The results are shown as mean   SD of triplicate 
cultures. (D) Synergistic effect of TPO and exogenous STAT5 1*6. 293 
cells were cotransfected with ST5BS-luciferase reporter gene, pMY-
human TPO receptor, and pGCDNsam-IRES-EGFP (GFP), or with pGCDN-
sam-STAT5A 1*6-IRES-EGFP (1*6), in the presence or absence of TPO 
(50 ng/ml). Fold luciferase activities are shown as the mean   SD of 
triplicate cultures (left). CD34–KSL cells transduced with pGCDNsam-
IRES-EGFP (G) or pGCDNsam-STAT5A 1*6-IRES-EGFP (1*6) were cultured 
in the presence of SCF and TPO. At d 6, the cells were washed and resus-
pended in the medium containing SCF alone (S) or both SCF and TPO 
(S T). After 24 h, cells were subjected to RT-PCR analysis on OSM gene 
expression (right). HPRT, hypoxanthine phosphoribosyltransferase.
Figure 4. Role of STAT3 in HSCs. (A) Growth and the content of CFU-
nmEM in culture of HSCs transduced with STAT3C. CD34–KSL cells trans-
duced with the indicated retroviruses were cultured in the presence of SCF 
and TPO, and their growth was monitored (left). At d 7 of culture, colony 
assays were performed to evaluate the content of HPP-CFC in culture (right). 
Expansion of CFU-nmEM is depicted on the bottom. The results are shown 
as mean   SD of triplicate cultures. *, statistically significant against GFP 
control ( 0.02). (B) Percent chimerism of donor cells in peripheral blood of 
recipients 12 wk after transplantation. CD34–KSL cells transduced with indi-
cated retroviruses were cultured in the presence of SCF and TPO. Competi-
tive repopulation assays were performed using ex vivo cultured cells at d 7 
corresponding to 30 initial CD34–KSL cells per recipient mouse. The data are 
presented as mean   SD (n   5). #, statistically not significant; WBC, white 
blood cell. (C) Absolute numbers of BM cells and KSL cells in STAT3 /– mice 5 
wk after conditional ablation of STAT3. The mean values are indicated as 
bars. (D) Growth and differentiation potential of STAT3 /– HSCs. 96 individ-
ual CD34–KSL HSCs from STAT3flox/– and STAT3 /– mice were sorted clonally 
into 96-well micro-titer plates in the presence of SCF, IL-3, TPO, and EPO. 
HPP-CFC and low-proliferative-potential colony-forming cell (LPP-CFC) 
numbers were evaluated retrospectively at d 14 (left). Colonies derived from 
HPP-CFC were examined for their composition with respect to colony-forming 
cells (right).JEM VOL. 202, July 4, 2005 173
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(Fig. 3 A). Although expression of STAT5 did not expand
CFU-nmEM under this stringent condition, it maintained
the numbers of CFU-nmEM over 7-d culture (Fig. 3, B and
C). To understand the molecular mechanism that explains a
synergistic biological effect of TPO and exogenous STAT5
1*6 in HSCs, we compared their capacities to induce tran-
scription of STAT5 target genes (Fig. 3 D). Both TPO stim-
ulation and exogenous STAT5 1*6 expression presented
moderate effects on transactivation of an artificial promoter
as well as on an authentic STAT5 target gene, Oncostatin M
(OSM). On the other hand, as expected, they showed a syn-
ergistic effect when combined with each other.
In contrast with STAT5, expression of STAT3C ad-
versely affected the maintenance of multipotential progeni-
tors. This adverse effect was manifest as a significantly de-
creased number of CFU-nmEM in culture and as somewhat
promoted myeloid differentiation, although the LTR capac-
ity of HSCs in vivo was not grossly affected (Fig. 4, A and B).
Alternately, expression of a dominant-negative STAT3
mutant (E434A/E435A), STAT3D (21) did not substantially
affect the proliferation or multilineage differentiation poten-
tial of HSCs (unpublished data). To understand further the
role of STAT3 in HSCs, we analyzed the effect of condi-
tional ablation of the STAT3 gene in HSCs. To establish
mice with a conditional knockout of STAT3 in hematopoi-
etic cells, STAT3flox/– and Mx1-Cre:STAT3flox/– mice were
injected with three doses of polyinocinic-polycytidylic acid
(pIpC), and their BM was analyzed 5 wk later. Only a trace
of STAT3 protein was detected in STAT3 /– BM, and, im-
portantly, phosphorylation of STAT3 was not detected at all
upon treatment with granulocyte colony-stimulating factor
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20042541/DC1), indicating efficient Cre-mediated ex-
cision of the floxed STAT3 gene in the BM.
The BM from STAT3 /– mice and from controls con-
tained similar numbers of cells in total and of hematopoietic
stem and multipotential progenitor cells (KSL cells) (Fig. 4
C). Moreover, single-cell growth assays demonstrated that
STAT3 /– CD34–KSL cells were able to form colonies at
frequencies comparable with those of controls and retained
multilineage differentiation potential (Fig. 4 D). These data
correspond well with previous analyses showing no signifi-
cant change in committed progenitor cell numbers in
STAT3 /– mice (22, 23) and indicate that the role of STAT3
in HSC is not essential.
To determine the mechanism whereby STAT5 activa-
tion induces CFU-nmEM expansion, we employed a
paired-daughter cell assay to see if overexpression of STAT5
mutants promotes symmetrical HSC division in vitro. After
24 h prestimulation, CD34–KSL cells were transduced with a
STAT5 1*6 retrovirus for another 24 h. After transduction,
single-cell cultures were initiated by micromanipulation.
When a single cell underwent cell division, the daughter
cells were separated again and were allowed to form colo-
nies. To evaluate the commitment process of HSCs while
excluding committed progenitors from this study, we se-
lected daughter cells that were retrospectively inferred to
have retained nmEM differentiation potential (4). Forced
expression of STAT5 1*6 unexpectedly did not change the
frequency of symmetrical cell division of daughter cells (Fig.
5), indicating that STAT5 does not grossly influence intrin-
sic decisions determining cell fate.
Selective activation of STAT5 maintains LTR-HSCs ex vivo 
and induces fatal MPD in vivo
To clarify whether LTR-HSCs were maintained in STAT5
culture, we performed competitive repopulation assays using
7-d and 10-d ex vivo–cultured cells corresponding to 30 ini-
tial CD34–KSL cells per recipient mouse. As previously re-
ported (24), repopulation with cells expressing STAT5 1*6
led to fatal MPD  4 wk after transplantation (Fig. 6 A).
Mice receiving cells expressing STAT5 1*7 mutant also de-
veloped MPD with a similar time course (Fig. 6 A). MPD in-
duced by STAT5 was characterized by marked leukocytosis
and splenomegaly. Histological analysis showed hypercellularity
of the BM with increased numbers of maturing myeloid ele-
ments and effacement of the splenic white pulp caused by ex-
tramedullary hematopoiesis (unpublished data). As previously
reported (24), STAT5-induced MPD accompanied a signifi-
cant expansion of nontransduced cells as demonstrated by
FACS analysis for GFP expression (Fig. 7 C and not depicted).
Although development of fatal MPD prohibited us from
evaluating the LTR capacity of cells in STAT5 1*6 and
Figure 5. Effect of STAT5 on symmetrical cell division of HSCs. 
CD34–KSL HSCs were transduced with either GFP or STAT5 1*6 retroviruses. 
After 24 h of transduction, cells were separated clonally by micromanipu-
lation. When a single cell underwent cell division, daughter cells were 
separated again by micromanipulation and were cultured further to permit 
full differentiation along myeloid lineages. The colonies were recovered for 
microscopy. Only the pairs whose parental cells were inferred to have retained 
neutrophil (n), macrophage (m), erythroblast (E), and Megakaryocyte (M) 
differentiation potential were selected. #, statistically not significant.ROLE OF STAT5 IN HEMATOPOIETIC AND LEUKEMIC STEM CELLS | Kato et al. 174
STAT5 1*7 ex vivo culture, mice reconstituted with cells
transduced with wild-type STAT5 did not develop MPD at
all, and a significant percentage of mice with STAT5 #2–
transduced cells survived more than 3 mo after transplanta-
tion, although most of them developed fatal MPD in the end
(Fig. 6 A). Of note, 12 wk after transplantation, HSCs trans-
duced with either wild-type STAT5 or STAT5 #2 showed
significantly higher repopulation than did the GFP control
(Fig. 6 B). The capacity of wild-type STAT5 or STAT5 #2
to maintain LTR-HSCs was prominent in 10-d ex vivo cul-
ture, in which no LTR activity was detected for the GFP
control (Fig. 6 B). The repopulating potential in a cell popu-
lation can be quantitated by calculating repopulation units
(RU) from the chimerism of donor cells and the number of
competitor cells. HSCs transduced with wild-type STAT5
or STAT5 #2 manifested fivefold and 15-fold higher RU,
respectively, compared with GFP controls when cultured for
7 d ex vivo (Fig. 6 B). We next performed competitive re-
population assays using 7-d ex vivo–cultured cells in the
presence of SCF alone. As expected from the capacity of
STAT5 to maintain CFU-nmEM ex vivo under this strin-
gent condition, HSCs transduced with either wild-type
STAT5 or STAT5 #2 established long-term repopulation,
although they somehow failed to contribute to B lym-
phopoiesis (Fig. 6 B). Moreover, mice infused with HSCs
that expressed STAT5 1*6 or STAT5 1*7 when maintained
with SCF alone developed fatal MPD, as had mice infused
with cells cultured in the presence of SCF and TPO (Fig. 6
A and unpublished survival data).
Leukemic stem cells could be derived from either HSCs
or from more restricted progenitors that have reacquired the
stem cell capability for self-renewal (13, 15, 25, 26). To un-
cover the role of constitutive activation of STAT5 in MPD
development directly, we next transduced CD34 KSL mul-
Figure 6. Selective activation of STAT5 enhances repopulation 
activity of HSCs and induces MPD. (A) Percent chimerism of donor cells 4 
wk after transplantation. CD34–KSL cells were transduced with the indicated 
retroviruses and were further cultured in the presence of SCF alone or of 
both SCF and TPO. Competitive repopulation assays were performed using 
ex vivo cultured cells at d 7 corresponding to 30 initial CD34–KSL cells per 
recipient mouse (SCF alone, n   10; SCF TPO, n   15). Percent chimerism 
of donor cells in the peripheral blood of surviving recipients is plotted as 
dots, and mean values are indicated as bars (left and middle). Survival of 
recipient mice infused with cultured cells in the presence of SCF and TPO 
was monitored and is shown as Kaplan-Meier plots (right). (B) Percent 
chimerism of donor cells in the peripheral blood of recipients 12 wk after 
transplantation. The data are expressed as mean   SD. Recipient mice with 
chimerism 1% in all white blood cells (WBC) were judged to be reconsti-
tuted (positive mice). *, statistically significant against GFP control ( 0.01). 
Myeloid, T-lymphoid, and B-lymphoid represent Gr-1  and/or Mac-1 , 
CD4  or CD8 , and B220  cells, respectively. (C) STAT5 targets CD34–KSL 
HSCs in the development of MPD. CD34 KSL multipotential progenitor cells 
as well as CD34–KSL HSCs were transduced with STAT5 1*6 and, 24 h after 
the initiation of transduction, cells were subjected to colony assays in the 
presence of SCF, TPO, IL-3, and EPO. Numbers of HPP-CFC and of each CFC 
type were evaluated at d 14 (left). *, statistically significant against GFP 
control ( 0.01). 6 d after the initiation of transduction, cells corresponding 
to 30 initial CD34–KSL cells or 150 initial CD34 KSL cells were injected into 
lethally irradiated recipient mice along with competitor cells. The peripheral 
blood data 4 wk after transplantation are presented (right).JEM VOL. 202, July 4, 2005 175
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tipotential progenitor cells with STAT5 1*6. Selective acti-
vation of STAT5 in CD34 KSL cells also promoted their
proliferation and multilineage differentiation (Fig. 6 C). No-
tably, however, CD34 KSL cells transduced with STAT5
1*6 failed entirely to repopulate BM and did not contribute
to MPD development (Fig. 6 C). Moreover, transduction of
STAT5 1*6 did not enhance the serial replating capacity of
CD34 KSL progenitor cells in vitro (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20042541/DC1).
These data indicate that activation of STAT5 alone does
not confer self-renewal capacity on committed progenitors or
the ability to induce and to maintain MPD. Conversely, only
HSCs originally retaining LTR capacity could induce MPD
in vivo when transduced with STAT5 1*6. According to this
evidence, we performed modified HSC measurement, i.e.,
measurement of MPD-initiating cell numbers in STAT5 1*6
ex vivo cultures. Using limiting dilution transplantation analy-
sis, the frequency of MPD-initiating cells in the 10-d ex vivo
culture was defined as 1 of 10 initial CD34–KSL cells at the
observation time point of 2 mo (Fig. S3 A, available at http://
www.jem.org/cgi/content/full/jem.20042541/DC1).
At day 10 of ex vivo culture, the GFP control culture
contained no LTR-HSCs (Fig. 6 B). Given that transduction
efficiency was  75% in this experiment, and that one of
three initial CD34–KSL cells exhibits LTR activity in vivo
(17), at least 4 of 10 initial LTR-HSCs were maintained in
the STAT5 1*6 culture. These data correspond well with re-
sults of clonality analyses of MPD, which demonstrated at
least three- to five-clone oligoclonality (Fig. S3 B). Longer
observation might note some increase in the frequency of
LTR-HSCs as inferred from the high-level contribution of
the donor cells in surviving mice at 2 mo (Fig. S3 A).
OSM is not principally responsible for MPD development 
induced by STAT5
OSM has been reported as a STAT5 target gene responsible
for the development of MPD induced by TEL/JAK2 (24).
In our RT-PCR analyses of STAT5 target gene expression,
OSM expression was significantly increased in HSCs trans-
duced with active-form STAT5 mutants (Fig. 7 A). To ana-
lyze the role of OSM in the development of MPD induced
by selective activation of STAT5, we transduced CD34–KSL
cells from OSM–/– and OSM receptor (OSMR)–/– mice with
STAT5 1*6, then transplanted them into lethally irradiated
mice. In mice infused with either OSM–/– or OSMR–/–
HSCs transduced with STAT5 1*6, MPD developed as
when wild-type HSCs were infused (Fig. 7 B), and expan-
sion of nontransduced cells was still observed (Fig. 7 C), in-
dicating that OSM is not the STAT5 target gene principally
involved in the development of MPD.
DISCUSSION
In this study, we directly showed that TPO activates STAT5
in HSCs (Fig. 1). Interestingly, IL-6, which failed to maintain
Figure 7. Oncostatin M signal is unnecessary for STAT5-induced 
MPD. (A) RT-PCR analysis of OSM gene expression in transduced HSCs. 
CD34–KSL cells transduced with the indicated retroviruses were cultured 
in the presence of SCF and TPO. At d 7 of culture, cells were subjected to 
RT-PCR. HPRT, hypoxanthine phosphoribosyltransferase. (B) Development 
of MPD with STAT5 1*6-transduced OSM–/– and OSMR–/– HSCs. CD34–KSL 
cells from OSM–/– or OSMR–/– HSCs were transduced with STAT5 1*6 and 
were further cultured in the presence of SCF and TPO. Competitive repop-
ulation assays were performed using ex vivo cultured cells at d 7 corre-
sponding to 30 initial CD34–KSL cells per recipient mouse. Kaplan-Meier 
plots of survival are presented. (C) Peripheral blood data 4 wk after trans-
plantation of OSM–/– HSCs are presented. Note that a significant percentage 
of Gr-1  and/or Mac-1  myeloid cells in MPD mice does not express GFP 
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HSC self-renewal in vivo in our previous study (6), did not
effectively induce STAT5 activation. These data support the
notion that STAT5 contributes to the self-renewal of HSCs.
Loss-of-function analyses involving STAT5 have
demonstrated its critical role in hematopoiesis. STAT5A/
STAT5B double-mutant mice (STAT5AB–/–) exhibit multi-
lineage peripheral blood cytopenias, BM progenitor-cell re-
duction, and a profound impairment of repopulation po-
tential in competitive BM transplantation assays (8, 9).
Although the number of HSCs is not significantly changed
in STAT5A/B–/– mice, a defect in STAT5A/B–/– HSC self-
renewal was uncovered by serial transplantation experiments
in which STAT5A/B–/– HSCs failed to provide consistent
engraftment in tertiary hosts (27). These hematopoietic de-
fects in STAT5A/B–/– mice, except for peripheral blood cell
counts, cannot be rescued by bcl-2 expression, indicating that
STAT5 plays an essential role in the maintenance and expan-
sion of self-renewing HSCs and progenitors (28). The role
of STAT5 in HSC self-renewal was demonstrated clearly by
gain-of-function analyses in this study. Expression of consti-
tutively active STAT5 mutants expanded multipotential
progenitors (Fig. 3) and promoted self-renewal of HSCs
(Fig. 6). During 7-d ex vivo culture, a net 20-fold CFU-
nmEM expansion and 15-fold higher repopulation activity
were obtained in STAT5 mutant cultures (Figs. 3 and 6). Of
note, expression of STAT5 mutants substantially slowed loss
of LTR-HSCs through successive cell divisions during 10-d
ex vivo culture (Fig. S3 A). Although expression of STAT5
mutants did not lead to an apparent HSC expansion, this re-
sult could be explained in part by the finding that it does not
grossly affect the frequency of symmetrical cell division of
CD34–KSL HSCs in vitro (Fig. 5). In this regard, the role of
STAT5 in HSC self-renewal contrasts sharply with that
of Bmi-1, an essential regulator of HSC self-renewal that
promotes symmetrical cell division of HSC in paired daugh-
ter-cell assays (4). However, the effect of STAT5 activation
is comparable to that of HoxB4 and of Bmi-1. Like these
HSC regulators, STAT5 could be a novel target for thera-
peutic manipulation of HSCs.
Notably, transduction of STAT5 mutants into CD34–
KSL HSCs supported their proliferation and multilineage
differentiation in the presence of SCF alone and allowed
CD34–KSL HSCs to give rise to significant numbers of high-
proliferative-potential colonies, including nmEM colonies
(Fig. 2 C). This observation directly supports a major role for
STAT5 as a downstream signaling molecule of early-acting
and lineage-restricted late-acting cytokines. Nevertheless,
the combination of exogenous STAT5 mutants with TPO
exhibited synergistic effects on HSCs as well as on the tran-
scription of STAT5 target genes (Figs. 3 and 6). These find-
ings indicate that other downstream signals activated by
TPO, including mitogen-activated protein kinase and phos-
phatidylinositol 3-kinase pathways might function synergisti-
cally with activated STAT5. Such signals or pathways also
might play a role in full activation of STAT5 through, for
example, its phosphorylation. In contrast to our data,
STAT5 recently has been demonstrated to promote eryth-
roid differentiation preferentially when expressed in human
CD34  cells (11). We also observed erythropoietin-indepen-
dent erythroblast expansion when we transduced human
CD34  cells with STAT5 1*6 (unpublished data). However,
in CD34–KSL HSCs or CD34 KSL progenitor cells, STAT5
1*6 expression did not promote expansion of erythroid-com-
mitted progenitor cells or erythroid differentiation in vitro.
Nor did it enhance their self-renewal capacity in vitro (Figs.
S2 and S4, available at http://www.jem.org/cgi/content/
full/jem.20042541/DC1).
These data suggest that the different effects of STAT5
1*6 in human and mouse are caused by a difference in spe-
cies rather than by a difference in target cells. Alternatively,
different in vitro culture conditions, i.e., with or without
stromal cells, might have affected the results.
In contrast to STAT5, STAT3 is activated efficiently by
signals mediated by gp130. Specific activation of gp130 by a
combination of IL-6 and soluble IL-6 receptor has been
demonstrated to expand human CD34  nonobese diabetic/
SCID-mouse repopulating cells ex vivo (29). This finding
suggests the participation of STAT3 in HSCs. However, re-
cent conditional gene-ablation analysis in hematopoietic cells
uncovered the specific role of STAT3 in negative regulation
of granulopoiesis by inducing expression of a signaling in-
hibitor, SOCS3 (22, 30). In this study, we further demon-
strated that STAT3 is not necessary for the maintenance of
HSCs in vivo or for the full unfolding in vitro of the capac-
ity of HSCs for proliferation and differentiation (Fig. 4, C
and D). On the other hand, selective activation of STAT3
counteracted TPO signaling with respect to expansion of
CFU-nmEM in vitro; instead, it committed HSCs to mye-
loid differentiation (Fig. 4 A). These findings correlate well
with those in neural precursor cells in which STAT3 plays a
major role in the commitment toward astrocyte lineage (31).
Although expression of a dominant-negative STAT3 report-
edly impairs the long-term hematopoietic repopulation ca-
pacity of HSCs (32), this finding should be interpreted care-
fully because dominant-negative forms of STAT3 potentially
inhibit the activity not only of STAT3 but also of STAT1, a
heterodimer partner for STAT3 (31). We previously re-
ported that IL-6 enhances mitogenic activity of CD34 KSL
cells but cannot maintain self-renewing HSCs in vitro (6).
This finding might be explained by an adverse effect of
STAT3 on HSC self-renewal.
Constitutive activation of STAT3 and STAT5 is de-
tected frequently in a variety of tumor types (16). Constitu-
tive activation of STAT5 often is observed in myeloid leu-
kemias of both acute and chronic types, whereas activation
of STAT3 is observed in lymphoid tumors. STAT5 signaling
has been shown to promote oncogenesis. In chronic mye-
logenous leukemia, STAT5 is activated persistently by the
BCR-ABL kinase, and in acute leukemia, it is activated per-
sistently by the FLT3 receptor tyrosine kinase with constitu-
tively activating internal tandem duplication (16). Of note,
constitutive STAT5 activation has been demonstrated to beJEM VOL. 202, July 4, 2005 177
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essential in a mouse model of MPD induced by TEL-JAK2
fusion protein (24). MPD is a group of disorders character-
ized by cellular proliferation of one or more hematopoietic
cell lineages distinct from acute leukemia. Chronic MPD
consists of four diseases, including polycythemia rubra vera,
primary thrombocythemia, agnogenic myeloid metaplasia,
and chronic myelogenous leukemia. Some evidence indi-
cates that MPDs are clonal diseases that arise from malignant
transformation of a single stem cell. In this study, we clearly
demonstrated that STAT5 targets CD34 KSL HSCs, but
not CD34 KSL progenitor cells, to induce MPD. Selective
activation of STAT5 in CD34 KSL cells promoted their
proliferation and multilineage differentiation. Importantly,
however, expression of STAT5 1*6 in CD34 KSL cells did
not enhance their in vitro self-renewal capacity (Fig. S2) and
failed to establish repopulation of hematopoiesis in vivo (Fig.
6 C). These data indicate that although STAT5 contributes
to progenitor expansion and to progenitor differentiation, it
does not confer LTR capacity on CD34 KSL progenitors.
They also indicate that the ability of STAT5 to promote
HSC self-renewal is most crucial in establishment of a leuke-
mic stem cell system. In this regard, the role of STAT5 in a
leukemic stem cell system is quite different from the roles of
MOZ-TIF2 and MLL-ENL oncogenes, which confer prop-
erties of leukemic stem cells on committed hematopoietic
progenitors (25, 26). In our previous study, other self-
renewal regulators such as HoxB4 and Bmi-1also failed to
confer LTR capacity on CD34 KSL progenitor cells (4).
These findings indicate that self-renewal is tightly regulated
in a multifactorial fashion.
The mechanism whereby STAT5 regulates HSC self-
renewal remains to be defined. In these experiments, the
biological effect of each STAT5 mutant, including CFU-
nmEM expansion, enhancement of HSC self-renewal ex
vivo, and the severity of MPD in vivo (Figs. 3 C and 6, A
and B) correlated well with each mutant’s transactivation ac-
tivity (Figs. 2 B and 7 A). For example, STAT5 1*6 and
STAT5 1*7 induced severe MPD, whereas wild-type
STAT5 did not induce MPD at all. These observations indi-
cate that certain STAT5 targets actually are responsible for
the HSC self-renewal process. Several genes have been
shown to be regulated by STAT5, including cyclin D1 (33),
p21, c-fos, Id-1, pim-1, Bcl-XL, CIS, and OSM. Among them,
cyclin D1 is preferentially expressed in primitive hematopoie-
tic cells (Iwama et al., unpublished data); cyclin D1 / D2 / 
D3 /  mice exhibit a profound defect in the expansion of
hematopoietic stem and progenitor cells (34). Recent find-
ings in Bmi-1–, ATM-, and JunB-deficient mice underscore
the impact of G1-S regulation by p16INK4a and p19ARF in
HSC self-renewal (4, 13, 35). Cyclin D1 could be one of the
candidate genes through which STAT5 could regulate this
process. Detailed expression profiling of STAT5-regulated
genes in HSCs would help us understand further the molec-
ular mechanisms underlying HSC self-renewal.
As previously reported (24), STAT5-induced MPD ac-
companied a significant expansion of nontransduced cells (un-
published data). The cell nonautonomous contribution to the
disease phenotype indicates involvement of growth factors in a
paracrine fashion. Dysregulation of several cytokines, including
TGF- , platelet-derived growth factor, and insulinlike growth
factor-1, in fact is implicated in the pathogenesis of MPD in
humans (36). In a mouse model of TEL/JAK2-induced MPD,
OSM has been implicated as one of the direct STAT5 targets
responsible for cell nonautonomous phenotype (24). However,
the ablation of neither OSM nor OSMR from HSCs had any
gross effect on the development of STAT5-induced MPD, in-
cluding cell nonautonomous phenotype (Fig. 7). We have pre-
viously reported that STAT5 activation promotes IL-6 gene
transcription in a NF- B–dependent manner (37). It will be
intriguing to pursue hitherto unidentified STAT5 targets that
contribute to the MPD phenotype in a paracrine fashion.
Selective activation of STAT5 in HSCs unveiled the spe-
cific role of STAT5 in normal HSCs as well as in leukemic
stem cells in a mouse model of MPD. STAT5 activation was
tightly involved in the development and maintenance of ab-
normal hematopoiesis of myeloid lineage. Further investiga-
tions of the role of STAT5 in normal and leukemic stem
cells should provide novel insights into the molecular mech-
anisms that regulate cancer stem cell systems.
MATERIALS AND METHODS
Mice. Stat3flox/– mice were generated by mating STAT3flox mice, in which
the DNA base pairs encoding the tyrosine phosphorylation site in Stat3 are
flanked by two loxP sites (STAT3flox/flox)(38), with STAT3 /– mice, in which
exons 20–22 are replaced by a neomycin resistance gene in the knockout al-
lele (39). To establish mice with a conditional knockout of STAT3 in he-
matopoietic cells, STAT3flox/– mice were mated with mice from a transgenic
line bearing Cre recombinase driven by the IFN-inducible Mx1 promoter
(40). Expression of Cre was induced by injecting mice intraperitoneally with
250  g of pIpC (Sigma-Aldrich) three times at 2-d intervals, as previously de-
scribed (40). 4-wk-old STAT3flox/– mice and Mx1-Cre:STAT3flox/– mice were
injected with pIpC and analyzed 5 wk later. OSM–/– mice and OSMR–/–
mice (41) were backcrossed at least eight times onto a C57BL/6 (B6-Ly5.2)
background. All experiments using mice received approval from the Tokyo
University Administrative Panel for the Animal Care.
Purification of mouse HSCs. Mouse HSCs (CD34 KSL cells) were pu-
rified from BM cells of 2-mo-old mice. In brief, low-density cells were iso-
lated on Lymphoprep (1.086 g/ml; Nycomed). The cells were stained with
an antibody cocktail consisting of biotinylated anti–Gr-1, –Mac-1, -B220,
-CD4, -CD8 and –Ter-119 monoclonal antibodies (BD Biosciences). Lin-
eage-positive cells were depleted with streptavidin-coupled magnetic beads
(M-280; Dynal). The remaining cells were stained further with FITC-conju-
gated anti-CD34, PE-conjugated anti–Sca-1, and allophycocyanin-conju-
gated anti–c-Kit antibodies (BD Biosciences). Biotinylated antibodies were
detected with streptavidin-Texas red (Invitrogen). Four-color analysis and
sorting were performed on a FACSVantage SE System (Becton Dickinson).
Retroviral constructs and cDNAs. Constitutively active forms of mouse
STAT3 and STAT5 (STAT3C, STAT5A, STAT5A #2, STAT5A 1*6, and
STAT5A 1*7) have been described (18–20). Murine wild-type STAT5A,
STAT5A #2, STAT5A 1*6, STAT5A 1*7, and STAT3C cDNAs were sub-
cloned into a site upstream of an IRES-EGFP construct in pGCDNsam, a
retroviral vector with an LTR derived from murine stem cell virus (4).
Transduction of mouse CD34–KSL cells. Recombinant retroviruses
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96-well micro-titer plates coated with recombinant fibronectin fragment
(Takara Shuzo, Co., Ltd.) at 150 cells/well and were incubated in  -MEM
supplemented with 1% FBS, 100 ng/ml mouse SCF, and 100 ng/ml human
TPO (PeproTech) for 24 h. The cells were transduced with a retrovirus
vector at a multiplicity of infection of 600 in the presence of protamine sul-
fate (10  g/ml; Sigma-Aldrich) and recombinant fibronectin fragment (1
 g /ml) for 24 h. After transduction, cells were further incubated in
S-Clone SF-O3 (Sanko Junyaku Co. Ltd.) supplemented with 1% FBS and
either 20 ng/ml SCF only or with 20 ng/ml SCF plus 50 ng/ml TPO and
were subjected to assays at the indicated time point. CD34 KSL were cul-
tured in the presence of 100 ng/ml of SCF, human TPO, and human IL-6
and were transduced similarly. In all experiments, transduction efficiency
was  80% as judged by GFP expression.
Colony assays. CD34–KSL cells transduced with indicated retroviruses
were plated in methylcellulose medium (StemCell Technologies Inc.) sup-
plemented with 50 ng/ml mouse SCF only or with 50 ng/ml mouse SCF,
20 ng/ml mouse IL-3, 50 ng/ml human TPO, and 2 units/ml human
erythropoietin (EPO; PeproTech). The culture dishes were incubated at
37 C in a 5% CO2 atmosphere. GFP  colony numbers were counted at d
14. Colonies derived from HPP-CFCs (colony diameter  1 mm) were re-
covered, cytospun onto glass slides, then subjected to May-Gruenwald-
Giemsa staining for microscopy.
Paired-daughter cell assays. CD34–KSL cells were transduced with in-
dicated retroviruses as described above. After 24 h of transduction, micro-
manipulation techniques were used to separate cells clonally into 96-well
microtiter plates in S-Clone SF-O3 supplemented with 0.1% BSA, 50 ng/
ml SCF, and 50 ng/ml TPO, as previously described (4). When a single cell
underwent cell division and gave rise to two daughter cells, daughter cells
were again separated into different wells by micromanipulation. Individual
paired daughter cells were further incubated in S-Clone SF-O3 supple-
mented with 10% FBS, 20 ng/ml SCF, 50 ng/ml TPO, 20 ng/ml IL-3, and
5 unit/ml EPO. The colonies generated from each daughter cell were re-
covered for microscopy.
Competitive repopulation assays. Competitive repopulation assays
were performed using the Ly5 congenic mouse system. In brief, hemato-
poietic cells from B6-ly5.2 mice were mixed with BM competitor cells
(B6-Ly5.1) and were transplanted into B6-ly5.1 mice irradiated at a dose of
9.5 Gy. In the case of Ly5.1 hematopoietic cells, cells were mixed with BM
competitor cells (B6-Ly5.2) and were transplanted into B6-ly5.2 mice. Af-
ter transplantation, peripheral blood of recipients was stained with biotinyl-
ated anti-Ly5.2 and PE-conjugated anti-Ly5.1 (BD Biosciences). Cells then
were stained with either a mixture of allophycocyanin-conjugated anti-
Mac-1 and anti-Gr-1 antibodies or a mixture of PE-conjugated anti-CD4
and anti-CD8 antibodies and PE-Cy7-conjugated anti-B220 antibody (BD
Biosciences). RU were calculated using Harrison’s method as follows:
RU   (percent donor cells)   (number of competitor cells)   10 5/100  
(percent donor cells). By definition, each RU represents the repopulating
activity of 105 BM cells. In this study, the number of BM competitors was
fixed as 2   105 cells. The test cell/competitor cell ratio defined above was
applied to Harrison’s formula as follows: RU   T/C ratio   2 (4).
Detection of phosphorylated STAT5 in CD34 KSL cells.
CD34 KSL cells were sorted in a serum-free culture medium drop supple-
mented with 0.1% BSA and either 100 ng/ml TPO or 100 ng/ml IL-6 on
fibronectin-coated slide glasses. The sorted cells were incubated at 37 C for
30 min. After fixation with 2% paraformaldehyde and blocking in 10% goat
serum for 1 h at room temperature, cells were incubated with a primary an-
tibody, anti-phospho-STAT5A/B, clone 8–5-2 (Upstate Biotechnology) at
a dilution of 1:500 for 12 h at 4 C. The cells then were washed and were
incubated with Alexa Fluor 488 goat anti-mouse secondary antibody (Invi-
trogen) at a dilution of 1:500 for 30 min at room temperature. Immunofluo-
rescence was observed with a Leica TCS SP2 AOBS confocal microscope.
RT-PCR. Semiquantitative RT-PCR was performed using normalized
cDNA by quantitative PCR using TaqMan rodent GAPDH control re-
agent (PerkinElmer), as described (4). Primer sequences are available from
the authors on request.
Luciferase assays. NIH 3T3 cells (5   104 cells) were seeded in a 24-well
plate and cultured for 24 h. Cells were then transfected with 200 ng of indi-
cated expression vector along with 100 ng of a reporter gene containing ei-
ther trimerized wild-type or mutated STAT5 binding sites from the cyclin
D1 promoter (3  D1-SIE1-Luc and 3  D1-SIE1m-Luc, respectively) (33)
and 600 pg of pRL-CMV, an expression vector of Renilla luciferase, using
Lipofectamine Plus reagent (Invitrogen). At 24 h after transfection, the cells
were deprived of serum for 12 h and then subjected to luciferase assays us-
ing the Dual-luciferase Reporter System (Promega). Relative firefly  lu-
ciferase activities were calculated by normalizing transfection efficiency to
Renilla luciferase activities. 293 cells were cotransfected with the ST5BS-Luc
luciferase reporter gene (42), pMY-human TPO receptor, and either
pGCDNsam-IRES-EGFP or pGCDNsam-STAT5A 1*6-IRES-EGFP in
the presence or absence of TPO (50 ng/ml), then similarly processed.
Western blotting. Jurkat cells transduced with the indicated retroviruses
were selected by cell sorting for GFP expression, and subjected to Western
blot analysis using anti–mouse STAT5 (L-20; Santa Cruz Biotechnology,
Inc.) and anti- -tubulin (Ab-1; Oncogene Science) antibodies.
Online supplemental material. Fig. S1 provides data for Cre-mediated
excision of STAT3. Fig. S2 provides data for serial replating capacity of
CD34 KSL HSCs and CD34 KSL progenitor cells transduced with STAT5
1*6. Fig. S3 provides the MPD-initiating cell numbers in the STAT5 1*6 ex
vivo culture and the clonality of STAT5 1*6–induced MPD. Fig. S4 provides
data for effect of STAT5 1*6 expression on erythroid commitment and ery-
throid progenitor expansion. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20042541/DC1.
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